OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!



Hormone Replacement Therapy Beneficial to Ovarian Cancer Patients

(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival. The 24-year, phase III international trial provides the... 

Small Trial Shows Promising Results for Nivolumab in Ovarian Cancer

(September 21, 2015) A small study found that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer. The phase II study of 20 patients had an overall response rate of 15% (3 responders); an additional 6... 

Q&A with OCRF Grantee Kris Wood, PhD

Kris Wood, PhD Q&A with Kris Wood, PhD Duke University 2014 Liz Tilberis Award   OCRF: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the central part of the state. My family lived in a house on my grandfather’s farm, which was a wonderful place to grow up–...